Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

3.2K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.2K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.8K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.8K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.8K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.8K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.8K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

4.4K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selected Patients with Benign Prostatic Enlargement and Detrusor Underactivity may Benefit from Prostate Surgery: An Exploratory Study.

Urology research & practice·2026
Same author

The antidepressant-like effect of adenosine A<sub>1</sub> receptor over-expression in forebrain neurons does not involve an altered adenosine-mediated control of excitatory synaptic transmission.

Neuropharmacology·2026
Same author

Annexin A1 and Dexamethasone Treatment in Hospitalized COVID-19 Patients: Impact on Disease Recovery and Evidence for an Interplay Between Proresolving Mediators.

Biomolecules·2026
Same author

Genetic deletion of adenosine A<sub>2A</sub> receptors attenuates memory deterioration and alterations of synaptic plasticity and metabolic controllers in the hippocampus and prefrontal cortex of aged mice.

GeroScience·2026
Same author

Neurophysiological In Vitro Model of Amyloid-β-Induced Deficits of Hippocampal LTP Involving Neuronal Adenosine A<sub>2A</sub> Receptor Dysfunction Through CD73.

Cells·2026
Same author

Hallmarks of healthy cognitive aging: Inter-individual differences in aging trajectories.

Ageing research reviews·2026

Related Experiment Video

Updated: Mar 30, 2026

Recombinant &#945;- &#946;- and &#947;-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

7.1K

Adenosine A2A Receptors Modulate α-Synuclein Aggregation and Toxicity.

Diana G Ferreira1,2,3,4, Vânia L Batalha1, Hugo Vicente Miranda1

  • 1Instituto de Medicina Molecular, Faculdade de Medicina Universidade de Lisboa.

Cerebral Cortex (New York, N.Y. : 1991)
|November 5, 2015
PubMed
Summary

Adenosine A2A receptor antagonists protect against Parkinson's disease by reducing alpha-synuclein inclusions. This neuroprotection involves NMDA receptor mechanisms, offering a potential therapeutic target for synucleinopathies.

Keywords:
Parkinson's diseaseadenosine A2A receptorshippocampusneuroprotectionα-Synuclein

More Related Videos

A Method to Study &#945;-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.8K
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human &#945;-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

6.8K

Related Experiment Videos

Last Updated: Mar 30, 2026

Recombinant &#945;- &#946;- and &#947;-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
09:36

Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays

Published on: August 13, 2017

7.1K
A Method to Study &#945;-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.8K
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human &#945;-Synuclein
14:45

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Published on: July 29, 2022

6.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Alpha-synuclein (aSyn) aggregation is central to Parkinson's disease (PD) and related synucleinopathies.
  • Adenosine A2A receptor (A2AR) antagonists show promise for PD treatment, but their mechanisms are not fully understood.

Purpose of the Study:

  • To investigate the neuroprotective mechanisms of A2AR blockade against aSyn-induced neurotoxicity.
  • To assess the impact of A2AR antagonism on synaptic plasticity and cell death.

Main Methods:

  • Utilized A2AR knockout (KO) mice and selective A2AR antagonists.
  • Assessed long-term potentiation (LTP) impairment and neuronal cell death in response to aSyn oligomers.
  • Examined aSyn aggregation and inclusion formation in cell models (SH-SY5Y) and primary neuronal cultures.

Main Results:

  • A2AR blockade or deletion rescued aSyn-induced LTP impairment via NMDA receptor-dependent pathways.
  • A2AR antagonists prevented cell death induced by aSyn oligomers.
  • A2AR antagonists reduced aSyn inclusions without affecting initial oligomerization.

Conclusions:

  • A2AR antagonists may exert neuroprotection by modulating later stages of aSyn aggregation, reducing toxic inclusions.
  • A2AR represents a viable therapeutic target for Parkinson's disease and other synucleinopathies.